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Abstract 25 
Hepatitis C virus (HCV) is a major cause of liver disease. Spontaneous resolution of infection is 26 
associated with broad, MHC class I- (CD8+) and class II-restricted (CD4+) T cell responses to 27 
multiple viral epitopes. Only 20% of patients clear infection spontaneously, however, most develop 28 
chronic disease. The response to chemotherapy varies; therapeutic vaccination offers an additional 29 
treatment strategy. To date, therapeutic vaccines have demonstrated only limited success in clinical 30 
trials. Vector-mediated vaccination with multi-epitope-expressing DNA constructs provides an 31 
improved approach. Highly-conserved, HLA-A2-restricted HCV epitopes and HLA-DRB1-restricted 32 
immunogenic consensus sequences (ICS, each composed of multiple overlapping and highly 33 
conserved epitopes) were predicted using bioinformatics tools and synthesized as peptides. HLA 34 
binding activity was determined in competitive binding assays. Immunogenicity and the ability of 35 
each peptide to stimulate naïve human T cell recognition and IFN-γ production were assessed in 36 
cultures of total PBMCs and in co-cultures composed of peptide-pulsed dendritic cells (DCs) and 37 
purified T lymphocytes, cell populations derived from normal blood donors. Essentially all predicted 38 
HLA-A2-restricted epitopes and HLA-DRB1-restricted ICS exhibited HLA binding activity and the 39 
ability to elicit immune recognition and IFN-γ production by naïve human T cells. The ability of DCs 40 
pulsed with these highly-conserved HLA-A2- and –DRB1-restricted peptides to induce naïve human 41 
T cell reactivity and IFN-γ production ex vivo demonstrates the potential efficacy of a multi-epitope-42 
based HCV vaccine targeted to dendritic cells. 43 
 44 
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Introduction 46 
Hepatitis C virus (HCV), a small single-stranded RNA virus, constitutes a major cause of liver 47 
disease [1]. The positive-sense genome encodes an ~3,000 amino acid poly-protein precursor, 48 
which is cleaved by cellular and viral proteases to yield three structural [core, envelope 1 (E1) and 49 
E2], and seven nonstructural (p7, NS2, NS3, NS4a, NS4b, NS5a and NS5b) proteins [2]. 50 
Spontaneous resolution of HCV infections is associated with broad, MHC class I- (CD8+) and class 51 
II-restricted (CD4+) T cell responses to multiple viral epitopes derived from these proteins [3,4]. 52 
Unfortunately, only 20% of patients clear infection spontaneously, most develop chronic disease [5]. 53 
Seventy to eighty percent of patients infected with HCV genotype 1 (the principal causative agent of 54 
hepatitis C in the U.S.) experience a sustained virologic response (SVR) following treatment that 55 
includes protease inhibitors, i.e., telaprevir or boceprevir, administered in conjunction with 56 
PEGylated interferon and ribavirin. A significant number of those treated remains infected, however, 57 
the cost of treatment is high, and the risk and severity of side effects are considerable [6,7]. New 58 
approaches to treating chronic HCV infections are urgently needed.   59 
Therapeutic vaccination concurrent with or without drug therapy offers an additional approach 60 
to treating chronic hepatitis C.  Indeed, the capacity of a significant percentage of patients to resolve 61 
acute infections spontaneously suggests that an effective therapeutic vaccine is a realistic goal.  A 62 
safe and effective vaccine must elicit broad, vigorous CD4+ and CD8+ T cells responses to 63 
conserved viral epitopes, which culminate in the elimination of HCV without causing liver pathology.  64 
Development of such a vaccine has proven problematic, however, due primarily to: infidelity of the 65 
viral RNA polymerase (NS5b), genetic diversity and the rapid emergence of viral variants [8].  To 66 
date, a number of vaccine strategies have demonstrated negligible or only limited success in clinical 67 
trials [9,10].  68 
Vaccination with HCV epitope expressing dendritic cells (DCs) offers a vector-mediated 69 
approach to treating chronic, HCV infected patients. DCs play a central role in CD4+ and CD8+ T cell 70 
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activation and the induction of immunity [11]. The potential effectiveness of DC-based vaccines in 71 
treating chronic hepatitis C has been demonstrated in animal models [12-14]. Moreover, in a recent 72 
Phase I clinical trial, chronically-infected patients vaccinated with monocyte-derived DCs pulsed with 73 
6 HCV-specific, HLA-class I-restricted peptides exhibited peptide-specific CD8 T cell responses [15]. 74 
These responses were not sustained, however, and there was no effect on viral load suggesting that 75 
HCV clearance might require vaccination with DCs that expressed a broader range of viral epitopes. 76 
Toward this end, immunoinformatics tools were used to predict 21 HLA-A*0201-restricted epitopes 77 
and 19 HLA-DRB1-restricted immunogenic consensus sequences (ICS, each composed of multiple 78 
epitopes), which were highly-conserved and encoded by HCV genotype 1. These predicted 79 
epitopes/ICS were synthesized as peptides and their capacities to bind HLA molecules were 80 
determined. Subsequently, their immunogenicity and ability to elicit the peptide-specific responses of 81 
naïve human T cells were validated in an in vitro peripheral blood mononuclear cell (PBMC) 82 
immunogenicity assay. Similarly, monocyte-derived DCs pulsed with these same peptides induced 83 
the epitope-specific responses of naïve CD4+ and CD8+ T cells in culture demonstrating the potential 84 
efficacy of a multi-epitope-based HCV vaccine that targets dendritic cells. 85 
 86 
 87 
88 
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Materials and Methods 88 
Genome Collection 89 
Hepatitis C viral sequences marked complete, representing a total of 871 genotype 1a and genotype 90 
1b polyproteins, were acquired from the Los Alamos sequence and immunology database [16,17].  91 
Conserved 9-mer search  92 
Nine-mer amino acid sequences, constituting the length of the peptide chain that fits into the binding 93 
groove of the HLA class I and class II molecules, were parsed out of the polyproteins and compared 94 
for identical parsed 9-mers in matching open reading fames of other genotype 1a or 1b isolates 95 
using the Conservatrix algorithm [18]. The potential immunogenicity of these identical 9-mer 96 
sequences was predicted using the computational method described below. 97 
Epitope mapping 98 
Approximately 50% of the population residing in the U.S. expresses cell-surface HLA-A2; essentially 99 
the entire population expresses one or more HLA-DRB1 alleles [19,20]. Consequently, each 9-mer 100 
was scored for its predicted potential to bind a panel of eight HLA-DRB1 alleles (DRB1*0101, 101 
DRB1*0301, DRB1*0401, DRB1*0701, DRB1*0801, DRB1*1101, DRB1*1301 and DRB1*1501) 102 
using EpiMatrix, a matrix-based algorithm for mapping T cell epitopes [21,22].  Additionally, all 103 
parsed 9-mers were scored for the potential to bind HLA-A2. Putative HLA-A2 epitopes were 104 
selected based on conservation in genotype 1a and b, EpiMatrix HLA A2-matrix predicted binding 105 
score, and reports of the ex vivo response of PBMCs obtained from HCV-infected patients. 106 
Immunogenic consensus sequences 107 
HLA-DRB1-restricted ICS were constructed using EpiAssembler, an algorithm that maximizes 108 
epitope density by assembling potentially immunogenic 9-mers (identified using EpiMatrix) into 18-109 
25 amino acid stretches [23]. To avoid potential cross-reactivity with the human proteome, any 110 
peptide that shared more than 7 identities per 9-mer frame was eliminated from further consideration 111 
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[24]. The final HLA-A2- and –DRB1-restricted peptide sequences were synthesized using 9-112 
fluoronylmethoxycarbonyl chemistry and purified >85% by 21st Century Biochemicals 113 
(Marlboro, MA).    114 
HLA Binding Assay  115 
The capacity of predicted epitopes (peptides) to bind multiple HLA-DRB1 alleles was assessed 116 
using a competitive, HLA class II binding assay as we described previously [24,25], using HLA 117 
molecules obtained from Bill Kwok, Benaroya Research Institute, Seattle, WA). Assays were 118 
performed for HLA-DRB1*0101, -DRB1*0301, -DRB1*0401, -DRB1*0701, -DRB1*1101 and -119 
DRB1*1501, alleles that provide broad representation of HLA class II that are prevalent in human 120 
populations [20]. IC50 values were estimated and the predicted peptides were classified as exhibiting 121 
very high (< 1 µM), high (1 µM - 10 µM), moderate (10 µM - 100 µM) or low (>100 µM) affinity.  122 
Peptides that exhibited very high, high or moderate affinity were considered binders (a more detailed 123 
classification is provided in the results section).  124 
The ability of predicted epitopes to bind HLA-A*0201 was assessed using a fluorescence 125 
polarization-based competitive peptide-binding assay according to published methods [26]. The 126 
concentration of experimental peptide that inhibited 50% binding of the FITC-labeled reference 127 
peptide (IC50) was determined. Experimental peptides were considered: high (IC50<5 µM), moderate 128 
(5 µM<IC50<50 µM) and low (IC50 = 50 - 100 µM) affinity binders. Peptides that failed to demonstrate 129 
dose-dependent inhibition or exhibited an IC50>100 µM were considered non-binders. 130 
Human subjects   131 
Whole-blood leukocyte reduction filters (blood filters; Sepacell RZ-2000, Baxter Healthcare 132 
Corporation, Irvine CA) were obtained from the Rhode Island Blood Center (Providence, RI).  These 133 
used, de-identified filters contain white cells derived from blood donated with informed consent by 134 
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healthy volunteers. The Lifespan Institutional Review Board (Rhode Island Hospital) approved this 135 
study.   136 
Peripheral blood mononuclear cell (PBMC) recovery and purification 137 
PBMCs were recovered from blood filters according to the methods of Meyer et al. [27]. Filters 138 
obtained within a 4-hour period following the leukocyte depletion step were back-flushed at room 139 
temperature with Ca- and Mg-free Hank’s basic salt solution containing sodium-EDTA and sucrose.  140 
The recovered leucocytes were purified by centrifugation on Ficoll-Paque Plus (1.077; Pharmacia, 141 
Uppsala, Sweden) gradient.  All donors expressed HLA-A*0201 and HLA-DRB1. 142 
Naïve PBMC cultures   143 
The peptide-specific responses of naïve human T cells were induced by culturing purified PBMCs 144 
under conditions described by others and modified in our laboratory [28]. PBMCs, 2.5 x 105/200 µl 145 
serum-free X-VIVO 15 medium (Lonza, Walkerville, MD) supplemented with glutamine, penicillin, 146 
streptomycin, and 50 U/ml recombinant human IL-2 (Roche Applied Science, Indianapolis, IN), were 147 
transferred to 96-well round bottom tissue culture plates and incubated 14 days with single (10 148 
µg/ml) HLA-A2- or -DRB1-restricted peptide. Half the spent medium was replaced with fresh medium 149 
containing IL-2, but no additional peptide, on days 3, 7 and 10 of the incubation period. 150 
ELISpot assays 151 
Cells collected after 14 days incubation under the culture conditions described were washed and 152 
resuspended in X-VIVO 15 medium supplemented with glutamine and antibiotics. The frequency of 153 
epitope-specific T lymphocytes was quantified using human IFN-γ ELISpot assay kits purchased 154 
from eBioscience, Inc. (San Diego, CA) and the protocol provided. Triplicate wells were inoculated 155 
with 50,000 cells/200 µl X-VIVO 15 medium and 10 µg/ml of the same peptide present during the 156 
pre-stimulation period.  Positive (phytohemagglutinin) and negative (0.1% DMSO) controls were 157 
included.  158 
159 
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DC priming of naïve T cell ex vivo  159 
Monocyte-derived DCs were generated in vitro in accordance with methods described by others 160 
[29]. CD14+ monocytes were purified from PBMCs back-flushed from blood filters using anti-CD14-161 
coated magnetic beads (Miltenyi Biotec; Auburn, CA). T lymphocytes were purified by negative 162 
selection using the human pan T cell isolation kit II also purchased from Miltenyi. Biotin-conjugated 163 
anti-mouse CD25 (Miltenyi) was added to the biotin-conjugated antibody cocktail supplied with the 164 
kit to eliminate CD25+ regulatory T cells.  Purified T lymphocytes were frozen and stored in liquid 165 
nitrogen for later use. The purified CD14+ monocytes were suspended in X-VIVO 15 medium that 166 
contained L-glutamine, penicillin, streptomycin, 100 ng/ml GM-CSF (PreproTech, Rocky Hill, NJ) 167 
and 25 ng/nl IL-4 (PeproTech), and cultured in 24-well, ultra-low attachment tissue culture plates 168 
(Corning Inc., Lowell, MA). Half the medium was replenished with fresh medium containing GM-CSF 169 
and IL-4 on day 3. The resultant DC population was collected on day 5; the cells were suspended in 170 
fresh X-VIVO medium, transferred to individual wells of a 96-well, round bottom plate (1 x 104 171 
cells/200 µl medium) and pulsed with single (10 µg/ml) peptides. On the following day, 25 ng/ml 172 
TNF-α (PeproTech) was added to promote DC maturation. After another 48 hours incubation, 100 µl 173 
of medium was removed, 6 x 105 naïve T lymphocytes (derived from the population purified and 174 
frozen above)/100 µl X-VIVO medium were added to each well; and the cells were co-cultured.  175 
To quantify the epitope-specific responses of purified T cells co-cultured with peptide-pulsed 176 
DCs, the cells were collected after 14 days incubation, centrifuged and resuspended in fresh X-VIVO 177 
15 medium.  The cells (50,000/100 µl) were transferred to IFN-γ capture antibody-coated ELISpot 178 
plates that contained 5,000 mature DCs/100 µl X-VIVO 15/well generated as described in the 179 
previous section and pulsed with the same peptide present during the initial co-culture period.  The 180 
remainder of the assay was conducted according to the supplier’s protocol referenced in the 181 
preceding section.   182 
 183 
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Results 184 
Epitope/ICS predictions  185 
A set of 21, HLA-A*0201-restricted epitopes were selected for synthesis from a set of more than 100 186 
highly conserved, high-scoring peptides predicted using the EpiMatrix and Conservatrix algorithms 187 
(Table I). Twenty of these epitopes scored in the top 1% (Z score ≥2.32) and one (peptide ID# 13) 188 
scored in the top 5% (Z score ≥1.64) of predicted binders, indicating a very high probability of HLA-189 
A*0201 binding. The amino acid sequence, A*0201 EpiMatrix Z Scores and relative conservation of 190 
these peptides among HCV genotypes 1a and 1b isolates (calculated using Conservatrix) are shown 191 
in Table II. 192 
Twenty-five HLA-DRB1-restricted ICS from the input HCV genotype 1a and 1b sequences 193 
were selected from a list of 79 that were predicted using the EpiAssembler algorithm; these varied 194 
from 15 to 27 amino acids in length. Each was composed of multiple, overlapping 9-mers (epitopes) 195 
capable of binding more than one HLA-DRB1 allele. The number of epitopes contained within each 196 
ICS predicted to bind across all 8 alleles was determined and ranged from 5 to 28 epitopes/ICS. 197 
Among the original 25 ICS, three exhibited significant homology to sequences found in the human 198 
genome and three overlapped protein junctions located within the HCV poly-protein; these six ICS 199 
were excluded from further study. The amino acid sequence, HLA-DRB1 EpiMatrix Z scores, 200 
number of predicted epitopes and conservation of the 19 remaining ICS among HCV genotypes 1a 201 
and 1b isolates are shown in Table II.  202 
Binding analyses 203 
Each predicted epitope/ICS was synthesized. HLA binding affinity and concurrence with 204 
computational predictions were determined. Positive predictions were defined as epitope scores 205 
≥1.64 on the EpiMatrix Z-scale and HLA binding of IC50<100µM. Overall, the proportion of 206 
predictions that concurred with binding  was ~90% (19/21) and 84% (96/114) for the HLA-A*0201-207 
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restricted peptides (Table III) and HLA–DRB1-restricted ICS (Table IV), respectively.  We expect no 208 
more than three to five percent of randomly selected peptides to bind to any given HLA. In the 209 
current case, approximately 85% of all predictions were confirmed, consistent with our previous 210 
experience. The small number of negative predictions present in this dataset makes statistical 211 
validation of the correlation between predicted binding and observed results difficult. We suggest 212 
that the correlation between prediction and observed outcome is self-evident.  213 
Epitope/ICS validation.  214 
All predicted A2-restricted epitopes and DRB1-restricted ICS that exhibited HLA binding affinity 215 
induced naïve T cell reactivity and IFN-γ production ex vivo, validating their immunogenicity.  216 
PBMCs obtained from healthy blood donors and cultured 14 days in the presence of single peptides 217 
subsequently exhibited peptide-specific IFN-γ production in ELISpot assays (Figure 1).  Similar 218 
results were obtained when purified, naïve human T lymphocytes were co-cultured with CD14+ 219 
monocyte-derived DCs pulsed with peptides. DCs pulsed with single HLA-A2-restricted or –DRB1-220 
restricted peptides induced marked increases in IFN-γ production by naïve human T cells in ELISpot 221 
assays (Figure 2). Notably, all peptide sequences induced IFN-γ production, but not to the same 222 
extent in co-cultures derived from different blood donors. 223 
 224 
 225 
226 
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Discussion 226 
Triple drug therapy (telaprevir or boceprevir, combined with PEGylated interferon and ribavirin) is 227 
recommended by the American Association for the Study of Liver Diseases as the standard 228 
treatment for unresolved HCV genotype 1 infections [30]. The SVR rate is improved significantly in 229 
patients who receive triple therapy compared to those treated with PEGylated interferon and ribavirin 230 
alone. While the outcome is improved, the overall success of triple drug therapy is limited by a 231 
variety of factors that include: general access to health care, cost of therapy, patient compliance, 232 
drug-drug interactions, emergence of anti-viral resistant variants, adverse side effects, and host 233 
factors that affect relative effectiveness [30,31].  Indeed, logistics and expense are major deterrents 234 
in treating chronically infected patients with antiviral drugs worldwide. As such, the development of a 235 
safe, effective and affordable vaccine represents the best hope for bringing the global hepatitis C 236 
epidemic under control, a stated objective in the US Department of Health and Human Services’ 237 
Viral Hepatitis Action plan [32].     238 
A safe and effective therapeutic vaccine for chronic hepatitis C must elicit broad, vigorous 239 
CD4+ and CD8+ T cell responses to conserved viral epitopes, which result in viral elimination in the 240 
absence of significant liver injury. To date, four distinct vaccine strategies have demonstrated only 241 
limited success in clinical trials: recombinant protein, peptide, genetic or DNA-based and vector-242 
mediated [9,10,33]. Recombinant protein vaccines are safe and well tolerated, but generally 243 
ineffective owing to their inability to induce a CD8+ T cells. Peptide-based HCV vaccines are similarly 244 
ineffective despite their ability to elicit weak, epitope-specific T cell responses; only a transient 245 
reduction in viral load was determined in a minority of chronically-infected patients [34,35]. Similarly, 246 
patients vaccinated with a codon-optimized HCV NS3/4A DNA construct exhibited only a transient 247 
reduction in serum viral load [36]. Finally, just half of the chronically-infected patients vaccinated in a 248 
Phase I clinical trial with modified vaccinia virus Ankara [MVA] engineered to express HCV NS3-5B 249 
proteins exhibited a temporary reduction in viral load [37].   250 
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Therapeutic vaccination with HCV epitope-expressing DCs concurrent with or without 251 
chemotherapy offers an additional vector-mediated approach to treating chronic, HCV-infected 252 
patients. The utility of this approach is supported by clinical trials demonstrating tumor regression 253 
and long-term survival in a subset of cancer patients administered antigen-pulsed DCs [38]. Indeed, 254 
FDA approval of Dendreon’s prostate cancer vaccine, Sipuleucel-T (Provenge), demonstrates the 255 
feasibility of developing a DC-vectored therapeutic vaccine for chronic hepatitis.  The potential 256 
efficacy of DC-based vaccines in treating chronic hepatitis C was demonstrated in a recent Phase I 257 
clinical trial in which patients vaccinated with monocyte-derived DCs pulsed with 6 HCV-specific, 258 
HLA-class I-restricted peptides exhibited peptide-specific CD8 T cell responses [15]. These 259 
responses were not sustained, however, nor was an effect on viral load discerned. The failed 260 
response of patients vaccinated with peptide-pulsed DCs in this clinical trial was attributed to the 261 
dearth of viral epitopes presented [15]. Immunization with DCs that express a broad array of HLA 262 
class I- and class II-restricted viral epitopes offers a means of significantly enhancing vaccine 263 
efficacy. 264 
The data presented herein support the EpiMatrix algorithm as an approach to high-volume 265 
genomic screening for vaccine candidates. Nineteen of 21 predicted, HLA class I-restricted peptides 266 
(>90%) were bound by HLA A*0201 in vitro, in accordance with previously published data [39]. All 267 
predicted HLA-class II-restricted peptides were bound by at least three HLA-DRB1 alleles, 268 
substantiating their promiscuity and potential recognition by a large, diverse human population [20]. 269 
A large, retrospective comparison conducted previously found EpiMatrix was >75% accurate across 270 
the HLA-DRB1 alleles studied here, and more accurate than all other epitope mapping algorithms in 271 
the public domain [22]. In the present study, 96 of the 114 HLA-DRB1-peptide pairs exhibited 272 
binding as predicted. Conceivably, a number of factors (e.g., peptide folding or aggregation under 273 
assay conditions, and the accuracy of immunoinformatic algorithms) contribute to the lack of a strict 274 
correlation between predicted and actual binding.   275 
 276 
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Conclusion 277 
IFN-γ is a principal mediator of anti-HCV-specific T cell responses [40,41]. All the predicted, HLA-278 
A2-restricted and –DRB1-restricted peptides that exhibited HLA binding activity also induced IFN-γ 279 
production in cultures of naïve human PBMCs, thus validating their immunogenicity and the 280 
prognostic accuracy of the EpiMatrix algorithm. Similarly, monocyte-derived DCs pulsed with the 281 
same peptides and co-cultured with naïve CD4+ and CD8+ human T cells induced epitope-specific 282 
IFN-γ production. This latter observation supports the therapeutic potential of DCs pulsed ex vivo 283 
with a broad array of HLA-A2- and –DRB1-restricted epitopes in treating chronic, HCV-infected 284 
patients. This approach suffers, however, from a number of practical limitations, foremost of which is 285 
the estimated high cost of treatment. Instead, we are currently exploring alternative strategies that 286 
include delivering the epitopes validated herein to DCs in situ. Regardless, epitope-driven 287 
immunotherapy alone or in combination with chemotherapy offers an additional means of treating 288 
the expanding patient population affected by chronic hepatitis C.  289 
 290 
 291 
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Table I. Predicted, HLA-A*0201-restricted HCV epitopes 434 
Peptide Name  Sequence    A*0201   Conservation  435 
 ID#   Z Score   1a 1b 436 
1 HCV_G1_NS4b_1917 WMNRLIAFA 2.48 100% 99% 437 
2  HCV_G1a_NS5b_2734  MLVCGDDLV 2.44 100%   nsa 438 
3  HCV_G1_NS4b_1765  HMWNFISGI 2.66   98% 94% 439 
4  HCV_G1_NS3_1451  SVIDCNTCV 2.60   98% 99% 440 
5 HCV_G1b_NS5b_2829 WLGNIIMYA 2.80     ns 97% 441 
6 HCV_G1_E2_615 RLWHYPCTV 3.24   35% 86% 442 
7 HCV_NS3_1586  YLVAYQATV  3.20   99% 86% 443 
8 HCV_G1_E2_685 ALSTGLIHL  2.68   74% 97% 444 
 9 HCV_G1_core_133 DLMGYIPLV  2.91   95% 97% 445 
10 HCV_G1_NS3_1074 CINGVCWTV  2.73   92% 34% 446 
11 HCV_G1_E1_323 MMMNWSPTT  2.54   70% 61% 447 
12 HCV_G1_E1_364 SMVGNWAKV 2.42   90% 80% 448 
13 HCV_G1_NS3_1274 GIDPNIRTGV 2.07   56% 16% 449 
14  HCV_G1_NS4b_1808 LLFNILGGWV 2.95   93% 91% 450 
15 HCV_G1_NS3_1607 QMWKCLIRL 2.76   72% 84% 451 
16 HCV_G1_NS5b_2559 IMAKNEVFCV 2.63   98% 75% 452 
17 HCV_G1_E1_277 YVGDLCGSV 2.62   91% 92% 453 
18 HCV_G1_E1_281 DLCGSVFLV 2.59   84% 74% 454 
19 HCV_G1_NS5b_2945 YLFNWAVRT 2.57   78% 61% 455 
20  HCV_G1_NS4b_1769  FISGIQYLA 2.51   98% 95% 456 
21 HCV_G1_NS3_1326 SILGIGTVL 2.32   90% 31% 457 
ans = not significant. 458 
459 
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Table II. Predicted, HLA-DRB1-restricted HCV ICS 459 
 460 
Peptide Name Sequence DRB1*0101  Predicted #    Conservation 461 
ID#  Z Score Epitopes   1a   1b 462 
1 HCV_G1_NS3_1246 AQGYKVLVLNPSVAATLGFG 2.15 20 >90% >90% 463 
2 HCV_G1_NS4b_1876 VDLLVNLLPAILSPGA  2.75 16 >90% >90% 464 
3 HCV_G1_NS5b_2879  LGNIIQRLHGLSAFSLHSY 2.85 15 >90% >90% 465 
4 HCV_G1_NS4b_1769  ISGIQYLAGLSTLPGNPA 2.54 11 >90% >90% 466 
5  HCV_G1_NS4b_1941 AARVTQILSSLTITQLLKRLHQWI 2.33 23 >90% >80% 467 
6  HCV_G1_NS5b_2440  KLPINALSNSLLRHH 3.00   8 >90% >80% 468 
7  HCV_G1_NS4b_1725 AEQFKQKALGLLQTASRQAE 1.76 12 >90% >80% 469 
8  HCV_G1a_NS5b_2485 LQVLKEVKAAASKVKANL 2.14 11 >90%      nsa 470 
9  HCV_G1_NS4b_1790 LMAFTAAVTSPLTTS 2.55 18 >80% >80% 471 
10  HCV_G1_NS5b_2840 WARMILMTHFFSVLIARDQLEQ 1.96 14 >80% >80% 472 
11  HCV_G1_E2_732 AYCLWMMLLISQAEAALELIT 1.87 16 >80% >70% 473 
12 HCV_G1a_E1_255 AAILRRHIDLLVGSATLCSALY 2.20 13 >80%      ns 474 
13 HCV_G1_NS3_1605 DQMWKCLIRLKPTLHGPTP 2.30 15 >70% >80% 475 
14 HCV_G1_NS5b_2941 CGKYLFNWAVRTKLKLT 2.61 11 >70% >60% 476 
15  HCV_G1a_E1_359 GIAYFSMVGNWAKVL 2.75   5 >70%      ns 477 
16  HCV_G1a_NS2_909 VPYFVRVQGLLRICALARKAV 2.58 24 >60%      ns 478 
17  HCV_G1b_NS5b_2898 PGEINRVASCLRKLGVPPLRAY 2.31 12      ns >80% 479 
18 HCV_G1b_NS5b_2913 VPPLRVWRHRARSVRAKLLSQGGRA 1.90 16      ns >70% 480 
19  HCV_G1b_NS2_748  LENLVVLNAASVAGAHW 2.54 17      ns >60% 481 
ans = not significant. 482 
 483 
 484 
 485 
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Table III. Predicted, HCV class-I restricted epitopes bind HLA-A*0201 486 
  487 
Peptide ID#   Sequence      IC50 488 
     489 
    1 HCV_G1_NS4b_1917  490 
    2 HCV_G1a_NS5b_2734 491 
    3 HCV_G1_NS4b_1765 492 
    4 HCV_G1_NS3_1451 493 
    5 HCV_G1b_NS5b_2829 494 
    6 HCV_G1_E2_615 495 
    7 HCV_NS3_1586  496 
    8 HCV_G1_E2_685 497 
    9 HCV_G1_core_133 498 
10 HCV_G1_NS3_1074 499 
11 HCV_G1_E1_323 500 
12 HCV_G1_E1_364 501 
13 HCV_G1_NS3_1274 502 
14 HCV_G1_NS4b_1808 503 
15 HCV_G1_NS3_1607 504 
16 HCV_G1_NS5b_2559 505 
17 HCV_G1_E1_277 506 
18 HCV_G1_E1_281 507 
19 HCV_G1_NS5b_2945 508 
20 HCV_G1_NS4b_1769 509 
21 HCV_G1_NS3_1326 510 
The peptides listed exhibited: IC50 high (IC50<5 µM, black bar); 511 
moderate (5 µM<IC50<50 µM, gray bar) or no (IC50>100 µM; white 512 
bar) affinity for HLA-A*0201 in a competitive binding assay. 513 
  514 
 515 
 516 
517 
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Table IV.  Promiscuous, class II-restricted HCV ICS bind multiple HLA-DRB1 alleles 517 
 518 
Peptide ID# Name *0101   *0301  *0401 *0701   *1101  *1501  519 
 520 
 1 HCV_G1_NS3_1246 521 
 2  HCV_G1_NS4b_1876   522 
 3 HCV_G1_NS5b_2879 523 
 4 HCV_G1_NS4b_1769 524 
 5 HCV_G1_NS4b_1941 525 
 6 HCV_G1_NS5b_2440 526 
 7  HCV_G1_NS4b_1725 527 
 8 HCV_G1_NS5b_2485 528 
 9 HCV_G1_NS5b_2840 529 
 10 HCV_G1_NS4b_1790 530 
 11 HCV_G1_E2_732 531 
 12  HCV_G1_E1_255 532 
 13 HCV_G1_NS3_1605 533 
 14 HCV_G1_NS5b_2941 534 
 15 HCV_G1_E1_359 535 
 16  HCV_G1_NS2_909 536 
 17 HCV_G1_NS5b_2898 537 
 18  HCV_G1_NS5b_2913 538 
 19 HCV_G1_NS2_748 539 
 540 
The peptides listed exhibited: IC50 high (IC50<10 µM, black bar); moderate (10 541 
µM<IC50<100 µM, gray bar) or low (IC50>100 µM; white bar) affinity for the alleles 542 
denoted in a competitive binding assay. 543 
544 
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Figure Legends 544 
Figure 1. Predicted HLA-A*0201- and HLA-DRB1-restricted HCV peptides induce epitope-specific 545 
IFN-γ production by naïve human PBMCs. PBMCs back-flushed from whole-blood leukocyte 546 
reduction filters were cultured with the HLA-A*0201-restricted (top) or HLA-DRB1-restricted (bottom) 547 
peptides listed. The cells were collected after 14 days incubation and IFN-γ ELISpot assays were 548 
performed. Each bar represents the average of triplicate wells minus the average negative control 549 
(0.1% DMSO + 2 SD) and the analysis of cells obtained from 5 and 9 healthy donors are shown in 550 
the top and bottom panels, respectively.       551 
Figure 2.  Peptide-pulsed DCs induce HCV epitope-specific IFN-γ production by naïve human T 552 
cells.  Purified T cells were co-cultured with monocyte-derived DCs pulsed with the HLA-A2-553 
restricted (top) and HLA-DRB1-restricted (bottom) peptides listed. The sensitized T cells were 554 
collected after 14 days and mixed with fresh, peptide-pulsed DCs and IFN-γ ELISpot assays were 555 
performed. Each bar represents the average of triplicate wells minus the average negative control 556 
(0.1% DMSO + 2 SD) and the analysis of cells obtained from 6 and 8 healthy donors shown in the 557 
top and bottom panels, respectively.       558 
 559 
 560 
561 
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Figure 1 562 
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Figure 2 567 
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